Obeldesivir Placebo

Phase 2

Gilead

Obeldesivir Placebo is one of 4 therapeutic programs targeting RSV Infection. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

RSV InfectionTerminated

RSV InfectionPhase 2

Terminated

Competition

Competitive Landscape

4 competitors in RSV Infection

#DrugCompanyPhaseTrials

Rsvpref

Pfizer

Phase 3

1 2

Obeldesivir

Gilead

Phase 2

1 3

Obeldesivir Placebo

Gilead

Phase 2

1 4

Zelicapavir

EEnanta Pharmaceuticals, Inc

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

RSV Infection1 trial

A Phase 2 Randomized, Placebo-controlled Study of the Safety and Efficacy of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) Infection

Terminated· Gilead logo

Gilead·Phase 2·NCT06585150·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Obeldesivir Placebo. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Obeldesivir Placebo. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Gilead company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: Gilead

Obeldesivir Placebo

Status by Indication[2][1]

Competitive Landscape

Trials by Indication[1]

RSV Infection1 trial

References

Drug Info

Quick Facts

Related News